Egle Therapeutics

Private

SuresnesHealthcare & Life Scienceshttps://www.egle-tx.com/

Last Round

Grant

Mar 2, 2026

Total Funding Raised

$61.6M

Company Overview

Egle Therapeutics is a biotechnology company that develops immunotherapies targeting regulatory T cells for the treatment of oncology and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

regulatory T cell therapyTreg therapyTreg-starverimmunotherapyTreg modulationoncologyautoimmune disease treatmentimmune modulationbiotechnologyprecision medicinedrug discoverynext-gen immunotherapycomputational biologybiopharmaceutical R&Dclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Egle Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Egle Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Egle Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Mar 2, 2026
Grant	Mar 17, 2025
Series A	Oct 22, 2021
Convertible Debt	Jun 11, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

John Celebi

Chief Executive Officer

Executive Team

Egle Therapeutics Investors

Notable investors and investment history

Egle Therapeutics investors
Investor	Rounds
EQT Life Sciences	Series A
Fund+	Series A
Bpifrance	Grant, Series A
Candriam	Series A
Bioqube Ventures	Series A
JDRF	Series A
Takeda Ventures	Convertible Debt, Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 7, 2026
John Celebi appointed as the new chief executive officer.

View all signals

Egle Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Egle Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Egle Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuresnes

Employee Range52

Year Founded2020

Last FundingMar 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.